Chemokine analogs for the treatment of human disease

Details Chemokine analogs for the treatment of human disease Chemokine analogs for the treatment of human disease

2006-08-15

2006-08-15

Andres, Janet L. (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C424S085100, C435S004000, C435S007930

Reexamination Certificate

active

07091310

ABSTRACT:
The present invention is concerned with chemokine analogs, including IL-8 analogs, IP-10 analogs, MIP-1α analogs, RANTES analogs, I-309 analogs, MCP-1 analogs, and CCL28 analogs, that are useful for the treatment of a variety of diseases and disorders, and as an adjunct to the treatment of a variety of diseases and disorders. A therapeutically effective amount of the chemokine analog may be administered to a patient in need of such treatment.

REFERENCES:
patent: 5401651 (1995-03-01), Walz
patent: 5665346 (1997-09-01), Clark-Lewis et al.
patent: 6515001 (2003-02-01), Saxena et al.
patent: 6693134 (2004-02-01), Saxena et al.
patent: 2002/0156034 (2002-10-01), Tudan et al.
patent: 2002/0165123 (2002-11-01), Tudan et al.
patent: 2003/0004136 (2003-01-01), Saxena et al.
patent: 2003/0045550 (2003-03-01), Saxena et al.
patent: 2003/0092674 (2003-05-01), Saxena et al.
patent: 2003/0125380 (2003-07-01), Saxena et al.
patent: 2003/0148940 (2003-08-01), Tudan et al.
patent: WO01/76615 (2001-10-01), None
patent: WO01/85196 (2001-11-01), None
Dermer, G. Bio/Technology, 12: 320, 1994.
Jain, R. Cancer and Metastasis Reviews, 9: 253-266, 1990.
U.S. Appl. No. 10/222,703, filed Aug. 16, 2002, Merzouk et al.
Belperio et al.,CXC Chemokines in Angiogenesis, Leukoc. Biol., vol. 68, pp. 1-8 (2000).
Buser et al.,Calcium Mobilization, Methods in Molecular Biology, vol. 138, pp. 143-148 (2000).
Clark-Lewis et al., J. Biol. Chem., vol. 269, pp. 16075-16081 (1994).
Daugherty et al., Methods in Molecular Biology, vol. 138,Chemokine Protocols, edited by Proudfoot et al., Human Press, Totowa, NJ, pp. 129-148 (2000).
DeNardo et al.,Choosing An Optimal Radioimmunotherapy Dose For Clinical Response, Cancer 94 (4 Suppl), pp. 1275-1286 (2002).
Francis et al., International Journal of Hematology, vol. 68, pp. 1-18 (1998).
Gazitt, J. Hematother Stem. Cell. Res., vol. 10, pp. 229-236 (2001).
Glimm et al.,Ex Vivo Treatment of Proliferating Human Cord Blood Stem Cells with Stroma-Derived Factor-1 Enhances Their Ability to Engraft NOD/SCID Mice,Blood, vol. 99(9), pp. 3454-3457 (2002).
Hattori et al., Blood, vol. 97, pp. 3354-3359 (2001).
Kaltsas et al.,The Value of Radiolabelled MIBG and Octreotide in the Diagnosis and Management of Neuroendocrine Tumours, Ann. Oncol. 12, Supp. 2, pp. S47-S50 (2001).
Kieseier et al.,Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10,Brain 125, pp. 823-824 (2002).
Lane et al., Blood, vol. 96, pp. 4152-4159 (2000).
Mach et al., Curr. Opin. Immunol., vol. 12, pp. 571-575 (2000).
Miller et al.,A novel polypeptide secreted by activated human T lymphocytes,J. Immunol., vol. 143(9), pp. 2907-2916 (1989).
Nagasawa, Int. J. Hematol., vol. 72, pp. 408-411 (2000).
Nomura et al., Int. J. Cancer, vol. 91, pp. 597-606 (2001).
Ponath et al.,Transwell Chemotaxis,Methods in Molecular Biology, vol. 138, pp. 113-120 (2000).
Schwarz et al., Nat. Rev. Drug Discov., vol. 1, pp. 347-358 (2002).
Wang et al., J. Biol. Chem., vol. 275, pp. 22313-22323 (2000).
Jennifer H. Dufour, et al.; “IFN-[gamma]-Inducible Protein 10 (IP-10; CXCL 10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking”; The Journal of Immunology; 2001; 167:7077-7083; pp. 3195-3204; The American Association of Immunologists.
U.S. Appl. No. 10/932,208, filed Aug. 31, 2004, Merzouk et al.
Hébert et al.,Sanning Mutagenesis of Interleukin-8 Identifies a Cluster of Residues Required for Recepthor Binding, The J. of Bilogical Chemistry, vol. 266, No. 28, Issue of Oct. 5, pp. 18989-18994 (1991).
Lejeune et al.,Interleukin-8 has antitumor effects in the rat which are not associated with polmorphonuclear leukocyte cytotoxicity, Cancer Immunol Immunother 38, pp. 167-170 (1994).

Affiliated with

Also associated with

Rating

Chemokine analogs for the treatment of human disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chemokine analogs for the treatment of human disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine analogs for the treatment of human disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3713488